Monitoring haloperidol exposure in body fluids and hair of children by liquid chromatography-high-resolution mass spectrometry

Therapeutic Drug Monitoring

Volumn 35, Issue 4, 2013, Pages 493-501

  Favretto, Donata ^a   Stocchero, Giulia ^b   Nalesso, Alessandro ^a   Vogliardi, Susanna ^a   Boscolo Berto, Rafael ^a   Montisci, Massimo ^a   Ferrara, Santo D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

children; hair; haloperidol intoxication; haloperidol metabolites; Orbitrap high resolution mass spectrometry

Indexed keywords

DRUG METABOLITE; HALOPERIDOL;

ARTICLE; BODY FLUID; CASE REPORT; CHILD; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HAIR LEVEL; DRUG INTOXICATION; DRUG MONITORING; DRUG STRUCTURE; DRUG URINE LEVEL; EMERGENCY WARD; FORENSIC TOXICOLOGY; HOSPITAL ADMISSION; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; POSITIVE ION ELECTROSPRAY; PRESCHOOL CHILD; PRIORITY JOURNAL;

BODY FLUIDS; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HAIR; HALOPERIDOL; HUMANS; INFANT; MALE; TANDEM MASS SPECTROMETRY;

EID: 84880573145     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182892d11     Document Type: Article

References (46)

1. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry. 1992;49:354-361.
2. Moffat AC, Osselton MD, Widdop W. Clarke's Analysis of Drugs and Poisons. 4th ed. London: Pharmaceutical Press; 2004.
3. Cummingham DG, Challapalli M. Hypertension in acute haloperidol poisoning. J Pediatr. 1979;95:489-490.
4. Kenyon-David D. Haloperidol intoxication. N Z Med J. 1981;93:165.
5. Satar S, Yilmaz HL, Gokel Y, et al. A case of child abuse: haloperidol poisoning of a child caused by his mother. Eur J Emerg Med. 2001;8: 317-319.
6. Scialli JV, Thornton WE. Toxic reactions from a haloperidol overdose in two children. Thermal and cardiac manifestations. JAMA. 1978;239:48-49.
7. Sinaniotis CA, Spyrides P, Vlachos P, et al. Acute haloperidol poisoning in children. J Pediatr. 1978;93:1038-1039.
8. Tsujimoto A, Tsujimoto G, Ishizaki T, et al. Toxic haloperidol reactions with observation of serum haloperidol concentration in two children. Dev Pharmacol Ther. 1982;4:12-17.
9. Yoshida I, Sakaguchi Y, Matsuishi T, et al. Acute accidental overdosage of haloperidol in children. Acta Paediatr. 1993;82:877-880.
10. Favretto D, Stocchero G, Vogliardi S, et al. Neonatal hair analysis by liquid chromatography-high-resolution mass spectrometry to reveal gestational exposure to venlafaxine. Ther Drug Monit. 2010;32:30-39.
11. Frison G, Favretto D, Vogliardi S, et al. Quantification of citalopram or escitalopram and their demethylated metabolites in neonatal hair samples by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2008;30:467-473.
12. Pufal E, Piotrowski P. Determination of haloperidol in fingernail/ toenails by LC-ESI-Ms [in Polish]. Arch Med Sadowej Kryminol. 2006;56:187-190.
13. Gerace E, Salomone A, Pellegrino S, et al. Evidence of Haldol (haloperidol) long-term intoxication. Forensic Sci Int. 2012;215:121-123.
14. Shen M, Xiang P, Wu H, et al. Detection of antidepressant and antipsychotic drugs in human hair. Forensic Sci Int. 2002;126:153-161.
15. Weinmann W, Muller C, Vogt S, et al. LC-MS-MS analysis of the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol in hair obtained from psychiatric patients. J Anal Toxicol. 2002;26:303-307.
16. Favretto D, Vogliardi S, Stocchero G, et al. High performance liquid chromatography-high resolution mass spectrometry and micropulverized extraction for the quantification of amphetamines, cocaine, opioids, benzodiazepines, antidepressants and hallucinogens in 2.5 mg hair samples. J Chromatogr A. 2011;1218:6583-6595.
17. Vogliardi S, Favretto D, Tucci M, et al. Simultaneous LC-HRMS determination of 28 benzodiazepines and metabolites in hair. Anal Bioanal Chem. 2011;400:51-67.
18. U.S. Department of Health and Human Services FDA. Guidance for Industry, Mass Spectrometry for Confirmation of the Identity of Animal Drug Residues. 2003.
19. EURACHEM. The Fitness for Purpose of Analytical Methods: A Laboratory Guide to Method Validation and Related Topics. LCG, Teddington; 1998. Available at: www.eurachem.otg.
20. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
21. U.S. Department of Health and Human Services FDA CDER CVM. Guidance for Industry. Bioanalytical Method Validation. 2001.
22. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216-224.
23. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030.
24. Arinobu T, Hattori H, Iwai M, et al. Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;776:107-113.
25. Cutroneo P, Beljean M, Luu RP, et al. Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography. J Pharm Biomed Anal. 2006;41:333-340.
26. Hoja H, Marquet P, Verneuil B, et al. Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization. J Chromatogr B Biomed Sci Appl. 1997;688:275-280.
27. Kratzsch C, Peters FT, Kraemer T, et al. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom. 2003;38:283-295.
28. Hempenius J, Steenvoorden RJ, Lagerwerf FM, et al. 'High throughput' solid-phase extraction technology and turbo ionspray LC-MS-MS applied to the determination of haloperidol in human plasma. J Pharm Biomed Anal. 1999;20:889-898.
29. Saar E, Gerostamoulos D, Drummer OH, et al. Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J Mass Spectrom. 2010;45:915-925.
30. Zhang G, Terry AV Jr, Bartlett MG. Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma. Rapid Commun Mass Spectrom. 2007;21:920-928.
31. Decaestecker TN, Clauwaert KM, Van Bocxlaer JF, et al. Evaluation of automated single mass spectrometry to tandem mass spectrometry function switching for comprehensive drug profiling analysis using a quadrupole time-of-flight mass spectrometer. Rapid Commun Mass Spectrom. 2000;14:1787-1792.
32. Fujii T, Hatanaka K, Sato G, et al. Selective determination of haloperidol in human serum: surface ionization mass spectrometry and gas chromatography with surface ionization detection. J Chromatogr B Biomed Appl. 1996;687:395-403.
33. Olmos-Carmona ML, Hernandez-Carrasquilla M. Gas chromatographicmass spectrometric analysis of veterinary tranquillizers in urine: evaluation of method performance. J Chromatogr B Biomed Sci Appl. 1999; 734:113-120.
34. Meyer MR, Maurer HH. Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem. 2012; 403:1221-1231.
35. Ojanperä I, Kolmonen M, Pelander A. Current use of high-resolution mass spectrometry in drug screening relevant to clinical and forensic toxicology and doping control. Anal Bioanal Chem. 2012;403: 1203-1220.
36. Fang J, Gorrod JW. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. Toxicol Lett. 1991;59:117-123.
37. Fang J, Gorrod JW. High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. J Chromatogr. 1993;614:267-273.
38. Gorrod JW, Fang J. On the metabolism of haloperidol. Xenobiotica. 1993;23:495-508.
39. Subramanyam B, Rollema H, Woolf T, et al. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun. 1990;166:238-244.
40. Eyles DW, McLennan HR, Jones A, et al. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther. 1994;56:512-520.
41. Van der Schyf CJ, Castagnoli K, Usuki E, et al. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem Res Toxicol. 1994;7:281-285.
42. Fang J, Baker GB, Coutts RT. Determination of 4-(4-chlorophenyl)-4- hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection. J Chromatogr B Biomed Appl. 1996;682: 283-288.
43. Eyles DW, McGrath JJ, Pond SM. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl). 1996; 125:214-219.
44. Eyles DW, Avent KM, Stedman TJ, et al. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci. 1997;60:529-534.
45. Thomas A, Geyer H, Schänzer W, et al. Sensitive determination of prohibited drugs in dried blood spots (DBS) for doping controls by means of a benchtop quadrupole/Orbitrap mass spectrometer. Anal Bioanal Chem. 2012;403:1279-1289.
46. Gallien S, Duriez E, Crone C, et al. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics. 2012.